SAFETY AND CARDIOTIC TOXIC ACTION OF DIFFERENT CYCLE OXYGENASE INHIBITORS FOR DURABLE PAIN SYNDROME

  • L.A. Ustinova
  • N.M. Seredinskaya
  • V.S. Khomenko
  • T.B. Khersonska
  • O.A. Evtodiev
  • V.I. Saglo
  • V.A. Barkevich
Keywords: pharmacological correction of pain syndrome, cardiotoxic effect of cyclooxygenase inhibitors, non-steroidal antiinflammatory drugs

Abstract

Some issues of pharmacological correction of pain syndrome, including those that develop in traumatic and / or inflammatory lesions in combat conditions, are outlined with the help of non-steroidal antiinflammatory drugs, different in selectivity to the key cyclooxygenase enzyme involved in metabolism and metabolism. amid pain and inflammation.
The aim of the study. To investigate the effect of non-steroidal antiinflammatory drugs, different in selectivity, on the survival of animals and to give a comparative description of their cardiotropic effects with prolonged use on the background of generalized pain syndrome.
Material and methods. Experimental methods, methods of data analysis and scientific generalization of results are used. The experimental procedures used were carried out in accordance with the international animal welfare requirements laid down in the European Convention for the Protection of Vertebrate Animals (Directive 86/ 609 / EC, Strasbourg) and are used for experimental and other scientific purposes.
Results and Discussion. Based on the studies, experimental data on the safety of daily long-term use (for 60 days) at therapeutic doses of diclofenac and nimesulide were provided. Concerns have been made regarding the long-term use of diclofenac and the need to control single and total doses of the drug, especially in the presence of pathology-associated pain.
Conclusions. The use of non-steroidal anti-inflammatory drugs, different in selectivity to cyclooxygenase, to provide medical assistance to military personnel in combat situations, when pain syndrome (prolonged pain) that develops through traumatic and / or inflammatory damage can lead to impaired cardiovascular function needs special attention from military medics

References

1. Ad’yuvantnaya bolezn (morfologiya, patogenez, eksperimentalnaya terapiya) / A.S. Saratikov, A.I. Vengerovskiy, T.P. Prischep . – Tomsk : izd-vo Tomsk, un-ta, 1983. – 104 s.
2. Belyanskaya N.E. Kliniko-patogeneticheskie osobennosti NPVP-indutsirovannoy gastropatii u bolnyih revmatoidnyim artritom i osteoartrozom : avtoref. … kand. med. nauk : 14.01.04 / N.E. Belyanskaya – Kazan, – 2010. – 23 s.
3. Voloschuk N. I. Stateviy dimorfIzm farmakokInetiki diklofenaku natrIyu u schurIv z ad’yuvantnim artritom / N. I. Voloschuk // FarmakologIya ta lIkarska toksikologIya. – 2009. –
№5 (12). – S. 33–37.
4. Voloschuk N. I. Stateviy dimorfIzm farmakologIchnoYi aktivnostI ta toksichnostI diklofenaku natrIyu u schurIv z ad’yuvantnim artritom / N. I. Voloschuk // MedichnI perspektivi. – 2009. - T. HIV. – №4. – S. 11–16.
5. Doklinicheskie issledovaniya lekarstvennyih sredstv : metod. rek.; pod red. A.V. Stefanova. – Kiev : Avitsenna, 2002 . – 528 s.
6. Eliseev M.S. Nimesulid v lechenii ostroy boli v revmatologicheskoy praktike: pochemu nisha poprezhnemu zanyata / M.S. Eliseev // Meditsinskiy sovet. – 2016. – №17. – S. 110–112.
7. Imanaeva A.Ya. Izuchenie protivovospalitelnoy aktivnosti lipoevoy kislotyi na modeli ad’yuvant-indutsirovannogo artrita kryis/ A.Ya. Imanaeva, L.N. Zalyalyutdinova, D.E. Tsyiplakov //
Fundamentalnyie issledovaniya. – 2013. – №6 (chast 3). – S. 596 – 600.
8. Karateev A.E. Tselekoksib, etorikoksib, meloksikam i nimesulid: dostoinstva i nedostatki / A.E. Karateev // Revmatologiya. Travmatologiya. Ortopediya. – 2011. – №1. – S. 9 – 19.
9. Karateev A.E. Kolichestvennaya i kachestvennaya otsenka riska oslozhneniy pri ispolzovanii nesteroidnyih protivovospalitelnyih preparatov kak osnova formirovaniya rekomendatsiy po ih kontrolyu i profilaktike / A.E. Karateev // Sovremennaya revmatologiya. – 2014. – T.8, №1. – S. 64 – 72.
10. Knyazkova I.I. Terapevticheskiy potentsial diklofenaka pri ostrom bolevom sindrome / I.I. Knyazkova // LIki UkraYini. – 2014. – №1. – S. 37- 42. – Rezhim dostupu: http://nbuv.gov.ua/UJRN/ likukr_2014_1_10.
11. Kozachok N.N. Lider XXI veka v lechenii bolevogo sindroma / N.N. Kozachok, M.N. Selyuk // UkraYinskiy medichniy chasopis. – 2010. – T.3, №77 – S. 55-58 Knyazkova I.I. Terapevticheskiy potentsial diklofenaka pri ostrom bolevom sindrome / I.I. Knyazkova // LIki UkraYini. – 2014. – №1. – S. 37 – 42. – Rezhim dostupu: http://nbuv.gov.ua/UJRN/
likukr_2014_1_10.
12. Kotova O.V. NPVP: v poiskah zolotoy seredinyi – sootnoshenie bezopasnost/effektivnost / O.V. Kotova // Spravochnik poliklinicheskogo vracha. – 2013. – №1. – S. 15-18.
13. Nasonov E.L. Primenenie nesteroidnyih protivovospalitelnyih preparatov i ingibitorov tsiklooksigenazyi-2 v nachale XXI veka / E.L. Nasonov // Russkiy meditsinskiy zhurnal. Revmatologiya. – 2003. – T.11, № 7. – S. 375-378.
14. Nasonov E.L. Rekomendatsii EULAR po lecheniyu revmatoidnogo artrita – 2013: obschaya harakteristika i diskussionnyie problemyi / E.L. Nasonov, D.E. Karateev, N.V. Chichasova // Nauchnoprakticheskaya revmatologiya. – 2013. – № 51. – S. 609–623.
15. Otsenka chastotyi razvitiya pobochnyih effektov pri dlitelnom ispolzovanii nimesulida v realnoy klinicheskoy praktike / A.E. Karateev, L.I. Alekseeva, E.A. Bratyigina, T.B. Ashirova // RMZh. – 2009. – T.17, №21. – S. 1466 –1471.
16. Petrovska H.P., Pentiuk O.O. Halmuvannia protsesiv biotransformatsii ksenobiotykiv pry adiuvantnomu artryti. Zviazok z aktyvnistiu zapalnoho protsesu ta oksydatyvnym i nitrozaktyvnym stresom / / Medychna khimiia. – 2005. – T.7, №2. – S. 5 – 9.
17. Petrovska H.P. Farmakokinetyka, analhetychnyi efekt ta toksychnist dyklofenaku natriiu u shchuriv z eksperymentalnym zapalnym protsesom / / Biomedical and Viosocial Anthropology. – 2004. – №3. – S. 87 – 91.
18. Petrovska H.P. Fermentni systemy koniuhatsii ksenobiotykiv u shchuriv z adiuvantnym artrytom, koreliatsiia z aktyvnistiu zapalnoho protsesu // Bukovynskyi medychnyi visnyk. – 2005. – T.9, №2. – S. 192 – 194.
19. Porivnialna otsinka protyzapalnoi aktyvnosti nimesulidu, dyklofenaku ta amlodypinu za adiuvantnoho artrytu / N.M. Seredynska, L.M. Kyrychok, M.A. Mokhort, H.V. Pavliuk // Farmakol. ta likarska toksykol. – 2013. – T. 33, №2. – S. 65 – 69.
20. Ratsionalnoe primenenie NPVP – balans effektivnosti i bezopasnosti (obzor literaturyi) / N.V. Zhuravleva, V.G. Kukes, A.B. Prokofev [i dr.] // Mezhdunar. zhurnal prikladnyih i fundamentalnyih issledovaniy. – 2016. – №6 (chast 4). – S. 687–696.
21. Ratsionalnoe ispolzovanie nesteroidnyih protivovospalitelnyih preparatov. Klinicheskie rekomendatsii / A.E. Karateev, E.L. Nasonov, V.T. Ivashkin, A.I. Martyinov [i dr.] // Nauchnoprakticheskaya revmatologiya. – 2018. – 56. – S. 1– 29; https://doi.org/10.14412/1995-4484-2018-1-29.
22. Seredynska N.M. Kombinovane zastosuvannia antyhipertenzyvnykh i nesteroidnykh protyzapalnykh preparativ: problemy ta perspektyvy / N. Seredynska, Z. Omelianenko, V. Khomenko // Naukovyi zhurnal MOZ Ukrainy. – 2015. – № 1(7). – S. 46–56.
23. Skorohodov A.P. Nimesulid: vozmozhnyie mehanizmyi deystviya, pokazaniya k naznacheniyu, osobennosti primeneniya v klinicheskoy praktike / A.P. Skorohodov, O.V. Polyanskaya // RMZh. – 2013. –T. 21, №30. – S.1546–1548.
24. Shuba N.M. NPVP-riski i vyibor bezopasnoy terapii / N.M. Shuba, T.D. Voronova, Yu.O. Kokunov / / Ukr. revmatol. zhurnal – 2018. – №1 (71) – S. 16–22.
25. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: five year prospective study / L. Innala, B. Moller, L. Ljiung [et
al.] // Arthritis Res. Ther. – 2011. – N13. – P. 131–137.
26. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison / C. Cannon, S. Curtis, G. FitzGerald [еt al.] // Lancet. – 2006. – Vol. 368(9549), N18. – P.1771–1781.
27. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis / S.Trelle, S. Reichenbach, S.Wandel [еt al.] // BMJ. – 2011.- N342. – Р. 7086–7116.
28. Effects of a cyclooxygenase-2 preferential inhibitor in young healthy dogs exposed to air pollution: a pilot study / L. Calderуn-Garcidueсas, A. MoraTiscareсo, G. Gуmez-Garza G. [et al.] // Toxicol. Pathol. – 2009. –Vol. 37, N5. – P. 644–660.
29. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors / W. B.White, J. Kent, A. Taylor et all. // Hypertension. – 2002. – N 39. – P. 929–934.
30. Europen convention for the protection of vertebrate animals used for experimental and other scientific purpose : Council of Europe. – Strasbourg, 1986. – 52 p.
31. Darren L. A. Animal models of rheumatoid arthritis / L.A. Darren, M. M. Ashley, B.Mc. Iain, Y.L. Foo // Eur. J. Immunol. – 2013. – Vol. 39, N 8. – P. 2040–2044.
32. Herrera J.A. Comparative evaluation of the effectiveness and tolerability of nimesulide versus rofecoxib taken once a day in the treatment of patients with knee osteoarthritis / J.A. Herrera, M. Gonzalez / / Am. J. Ther. – 2003. – Vol.10, N6. – P. 468–472.
33. Koo B.K. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent: an openlabel randomized controlled study / B.K. Koo, Y.S. Kim, K.W. Park // Lancet. – 2007. – N370. – P. 567–574.
34. Lanas A. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study / A. Lanas, J. Tomero, J.L. Zamorano // Ann Rheum. Dis. – 2010. – Vol. 69, N8. – P. 1453–1458.
35. McInnes I.B. The pathogenesis of rheumatoid arthritis / I.B. McInnes, G. Schett // N Engl. J Med. – 2011. – Vol. 365, N23. – P. 2205–2219.
36. Nelson Mk. Drug treatment of elevated blood pressure / Mk. Nelson // Australian Prescriber. – 2010. – N33. – P. 108–112.
37. Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti–inflammatory drugs / G.E. Senna, G. Passalacqua, A. Dama [et al.] // Eur. Ann. Allergy Clin. Immunol. – 2003. – Vol. 5, N10. – P. 393–396.
38. Nimesulide: 25 years later / C. Mattia, S. Ciarcia, A. Muhindo, F. Colluzzi // Minerva Med. – 2010. – Vol.101, N4. – P. 285–293.
39. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study / J. Lindhardsen, O. Ahlehoff, G.H. Gislason [et al.] // BMJ. – 2012. – Vol. 344, N8. – P. 1257–1261.
40. Risk of congestive heartfailure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect? / M. Hudson, E. Rahme, H. Richard, L. Pilote // Arthritis Rheum. – 2007. – Vol. 57, N33. – P. 516–523.
41. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular even / V. Strand / / Lancet. – 2007. – N 370(9605). – P. 2138–2151.
Published
2019-09-11
How to Cite
Ustinova, L., Seredinskaya, N., Khomenko, V., Khersonska, T., Evtodiev, O., Saglo, V., & Barkevich, V. (2019). SAFETY AND CARDIOTIC TOXIC ACTION OF DIFFERENT CYCLE OXYGENASE INHIBITORS FOR DURABLE PAIN SYNDROME. Ukrainian Journal of Military Medicine, 19(3), 95-108. Retrieved from https://ujmm.org.ua/index.php/journal/article/view/63